These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30675823)

  • 1. Strategies to optimize drug half-life in lead candidate identification.
    Broccatelli F; E C A Hop C; Wright M
    Expert Opin Drug Discov; 2019 Mar; 14(3):221-230. PubMed ID: 30675823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lead compound optimization strategy (1)--changing metabolic pathways and optimizing metabolism stability].
    Wang J; Liu H
    Yao Xue Xue Bao; 2013 Oct; 48(10):1521-31. PubMed ID: 24417078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.
    Bell LC; Wang J
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1131-55. PubMed ID: 22681474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-silico ADME models: a general assessment of their utility in drug discovery applications.
    Gleeson MP; Hersey A; Hannongbua S
    Curr Top Med Chem; 2011; 11(4):358-81. PubMed ID: 21320065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties and in silico ADME modeling in drug discovery.
    Honório KM; Moda TL; Andricopulo AD
    Med Chem; 2013 Mar; 9(2):163-76. PubMed ID: 23016542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating human ADME properties, pharmacokinetic parameters and likely clinical dose in drug discovery.
    Lucas AJ; Sproston JL; Barton P; Riley RJ
    Expert Opin Drug Discov; 2019 Dec; 14(12):1313-1327. PubMed ID: 31538500
    [No Abstract]   [Full Text] [Related]  

  • 8. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of lipophilicity in drug discovery and design.
    Arnott JA; Planey SL
    Expert Opin Drug Discov; 2012 Oct; 7(10):863-75. PubMed ID: 22992175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization.
    Miller RR; Madeira M; Wood HB; Geissler WM; Raab CE; Martin IJ
    J Med Chem; 2020 Nov; 63(21):12156-12170. PubMed ID: 32633947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of physicochemical and molecular properties in drug design: navigation in the "drug-like" chemical space.
    Vallianatou T; Giaginis C; Tsantili-Kakoulidou A
    Adv Exp Med Biol; 2015; 822():187-94. PubMed ID: 25416989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. truPK -- human pharmacokinetic models for quantitative ADME prediction.
    Subramanian K
    Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):555-64. PubMed ID: 16863461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early ADME in support of drug discovery: the role of metabolic stability studies.
    Thompson TN
    Curr Drug Metab; 2000 Nov; 1(3):215-41. PubMed ID: 11465046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of an ADME enabling selection and visualization tool for drug discovery.
    Stoner CL; Gifford E; Stankovic C; Lepsy CS; Brodfuehrer J; Prasad JV; Surendran N
    J Pharm Sci; 2004 May; 93(5):1131-41. PubMed ID: 15067690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of HT-ADME in drug discovery.
    Morgan D
    Bioanalysis; 2011 Nov; 3(21):2385-7. PubMed ID: 22074279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.
    Stoner CL; Cleton A; Johnson K; Oh DM; Hallak H; Brodfuehrer J; Surendran N; Han HK
    Int J Pharm; 2004 Jan; 269(1):241-9. PubMed ID: 14698595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipophilicity and biomimetic properties to support drug discovery.
    Tsopelas F; Giaginis C; Tsantili-Kakoulidou A
    Expert Opin Drug Discov; 2017 Sep; 12(9):885-896. PubMed ID: 28644732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.